| [1] |
方友强, 周祥福. 2020版美国国立综合癌症网络前列腺癌临床实践指南要点解读 [J/CD]. 中华腔镜泌尿外科杂志(电子版), 2020, 6(14): 405-408.
|
| [2] |
Prostate Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[Z]. 2021,
URL
|
| [3] |
Beltran H, Romanel A, Conteduca V, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer [J]. J Clin Invest, 2020, 130(4): 1653-1668.
|
| [4] |
Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer: a prospective, population-based study in sweden [J]. JAMA, 1997, 277(6): 467-471.
|
| [5] |
Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer[J]. J Clin Oncol, 2015, 33(3): 272-277.
|
| [6] |
Dearnaley DP, Saltzstein DR, Sylvester JE, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial [J]. Eur Urol, 2020, 78(2): 184-192.
|
| [7] |
Lu-yao GL, Albertsen PC, Moore DF, et al. Fifteen-Year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer [J]. JAMA Internal Med, 2014, 174(9): 1460-1467.
|
| [8] |
Potosky AL, Haque R, Cassidy-bushrow AE, et al. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer[J]. J Clinical Oncol, 2014, 32(13): 1324-1330.
|
| [9] |
Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer[J]. N Engl J Med, 2020, 382(23): 2187-2196.
|
| [10] |
Slater H. Phase 3 HERO trial finds relugolix to be superior to leuprolide in prostate cancer[J]. Oncology (Williston Park, NY), 2020, 34(7): 252.
|
| [11] |
Weiner AB, Nettey OS, Morgans AK. Management of metastatic hormone-sensitive prostate cancer (mhspc): an evolving treatment paradigm[J]. Curr Treat Options Oncol, 2019, 20(9): 69.
|
| [12] |
Miller DR, Ingersoll MA, Teply BA, et al. Targeting treatment options for castration-resistant prostate cancer [J]. Am J Clin Exp Urol, 2021, 9(1): 101-120.
|
| [13] |
Hammerich KH, Donahue TF, Rosner IL, et al. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer[J]. Urol Oncol, 2017, 35(7): 460.e21-e28.
|
| [14] |
Sengoz M, Abacioglu U, Cetin İ, et al. PSA bouncing after external beam radiation for prostate cancer with or without hormonal treatment[J]. Eur Urol, 2003, 43(5): 473-477.
|
| [15] |
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(10): 1432-1443.
|
| [16] |
Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial [J]. Lancet Oncol, 2018, 19(7): 975-986.
|
| [17] |
Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration[J]. J Clin Oncol, 2020, 38(32): 3763-3772.
|
| [18] |
Abida W, Cheng ML, Armenia J, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade [J]. JAMA Oncology, 2019, 5(4): 471-478.
|